Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy

References

• Barger JF, Plas DR. Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis. Endocr Relat Cancer. 2010;17(4):R287–304.
   PubMed Web of Science ®Google Scholar
• Gomes AP, Blenis J. A nexus for cellular homeostasis: the interplay between metabolic and signal transduction pathways. Curr Opin Biotechnol. 2015;34:110–117.
   PubMed Web of Science ®Google Scholar
• Krejčí A. Metabolic sensors and their interplay with cell signalling and transcription. Biochem Soc Trans. 2012;40(2):311–323.
   PubMedGoogle Scholar
• de Souza ACS, Justo GZ, de Araújo DR, et al. Defining the molecular basis of tumor metabolism: a continuing challenge since Warburg’s discovery. Cell Physiol Biochem. 2011;28(5):771–792.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Galleggiante V, Rutigliano M, et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget. 2015;6(15):13371–13386.
   PubMedGoogle Scholar
• Chen J.Q, Russo J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. Biochim Biophys Acta. 2012;1826(2):370–384.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010;330(6009):1340–1344.
   PubMed Web of Science ®Google Scholar
• Yeung SJ, Pan J, Lee M.H. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci. 2008;65(24):3981–3999.
   PubMed Web of Science ®Google Scholar
• Gaglio D, Metallo CM, Gameiro PA, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011;7:523.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang C, Hu W, et al. Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett. 2015;356(2 Pt A):197–203.
   PubMed Web of Science ®Google Scholar
• Li Z, Li J, Bi P, et al. Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state. Mol Cell Biol. 2014;34(19):3642–3661.
   PubMed Web of Science ®Google Scholar
• Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol. 2013;15(6):555–564.
   PubMed Web of Science ®Google Scholar
• Cargnello M, Tcherkezian J, Roux PP. The expanding role of mTOR in cancer cell growth and proliferation. Mutagenesis. 2015;30(2):169–176.
   PubMed Web of Science ®Google Scholar
• Yecies JL, Manning BD. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl). 2011;89(3):221–228.
   PubMed Web of Science ®Google Scholar
• Howell JJ, Ricoult SJH, Ben-Sahra I, et al. A growing role for mTOR in promoting anabolic metabolism. Biochem Soc Trans. 2013;41(4):906–912.
   PubMedGoogle Scholar
• Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2006;18(1):77–82.
   PubMed Web of Science ®Google Scholar
• Bläker H, Helmchen B, Bönisch A, et al. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. Scand J Gastroenterol. 2004;39(8):748–753.
   PubMed Web of Science ®Google Scholar
• Alo PL, Visca P, Marci A, et al. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer. 1996;77(3):474–482.
   PubMed Web of Science ®Google Scholar
• Kao Y.C, Lee S-W, Lin L.C, et al. Fatty acid synthase overexpression confers an independent prognosticator and associates with radiation resistance in nasopharyngeal carcinoma. Tumour Biol. 2013;34(2):759–768.
   PubMedGoogle Scholar
• Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008;26(35):5713–5720.
   PubMed Web of Science ®Google Scholar
• Duan J, Sun L, Huang H, et al. Overexpression of fatty acid synthase predicts a poor prognosis for human gastric cancer. Mol Med Rep. 2016;13(4):3027–3035.
   PubMed Web of Science ®Google Scholar
• Cheng J, Ondracek RP, Mehedint DC, et al. Association of fatty-acid synthase polymorphisms and expression with outcomes after radical prostatectomy. Prostate Cancer Prostatic Dis. 2015;18(2):182–189.
   PubMed Web of Science ®Google Scholar
• Ventura R, Mordec K, Waszczuk J, et al. Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression. EBioMedicine. 2015;2(8):808–824.
   PubMed Web of Science ®Google Scholar
• Burns CP, Spector AA. Membrane fatty acid modification in tumor cells: a potential therapeutic adjunct. Lipids. 1987;22(3):178–184.
   PubMed Web of Science ®Google Scholar
• Turrado C, Puig T, García-Cárceles J, et al. New synthetic inhibitors of fatty acid synthase with anticancer activity. J Med Chem. 2012;55(11):5013–5023.
   PubMed Web of Science ®Google Scholar
• Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 2006;9(4):358–365.
   PubMed Web of Science ®Google Scholar
• Kuhajda FP, Piantadosi S, Pasternack GR. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med. 1989;321(10):636–641.
   PubMed Web of Science ®Google Scholar
• Kuhajda FP, Jenner K, Wood FD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A. 1994;91(14):6379–6383.
   PubMed Web of Science ®Google Scholar
• Smith S, Witkowski A, Joshi AK. Structural and functional organization of the animal fatty acid synthase. Prog Lipid Res. 2003;42(4):289–317.
   PubMed Web of Science ®Google Scholar
• Jones SF, Infante JR. Molecular pathways: fatty acid synthase. Clin Cancer Res. 2015;21(24):5434–5438.
   PubMed Web of Science ®Google Scholar
• Wakil SJ. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry. 1989;28(11):4523–4530.
   PubMed Web of Science ®Google Scholar
• Smith S. The animal fatty acid synthase: one gene, one polypeptide, seven enzymes. Faseb J. 1994;8(15):1248–1259.
   PubMed Web of Science ®Google Scholar
• Kusakabe T, Maeda M, Hoshi N, et al. Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. J Histochem Cytochem. 2000;48(5):613–622.
   PubMed Web of Science ®Google Scholar
• Dhanasekaran SM, Dash A, Yu J, et al. Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. Faseb J. 2005;19(2):243–245.
   PubMedGoogle Scholar
• Pizer ES, Kurman RJ, Pasternack GR, et al. Expression of fatty acid synthase is closely linked to proliferation and stromal decidualization in cycling endometrium. Int J Gynecol Pathol. 1997;16(1):45–51.
   PubMed Web of Science ®Google Scholar
• Anderson SM, Rudolph MC, McManaman JL, et al. Key stages in mammary gland development. Secretory activation in the mammary gland: it’s not just about milk protein synthesis! Breast Cancer Res. 2007;9(1):204.
   PubMed Web of Science ®Google Scholar
• Weiss L, Hoffmann GE, Schreiber R, et al. Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol Chem Hoppe Seyler. 1986;367(9):905–912.
   PubMed Web of Science ®Google Scholar
• Baker N, Mead J Jr., Kannan R. Hepatic contribution to newly made fatty acids in adipose tissue in rats and inhibition of hepatic and extrahepatic lipogenesis from glucose by dietary corn oil. Lipids. 1981;16(8):568–576.
   PubMed Web of Science ®Google Scholar
• Laux T, Schweizer M. Dietary-induced pre-translational control of rat fatty acid synthase. Biochem J. 1990;266(3):793–797.
   PubMed Web of Science ®Google Scholar
• Yoshii Y, Furukawa T, Oyama N, et al. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome. PLoS One. 2013;8(5):e64570.
   PubMed Web of Science ®Google Scholar
• Chen H.W, Chang Y.F, Chuang H-Y, et al. Targeted therapy with fatty acid synthase inhibitors in a human prostate carcinoma LNCaP/tk-luc-bearing animal model. Prostate Cancer Prostatic Dis. 2012;15(3):260–264.
   PubMed Web of Science ®Google Scholar
• Zaytseva YY, Rychahou PG, Gulhati P, et al. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res. 2012;72(6):1504–1517.
   PubMed Web of Science ®Google Scholar
• Orita H, Coulter J, Lemmon C, et al. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res. 2007;13(23):7139–7145.
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. Int J Mol Med. 2005;15(1):33–40.
   PubMed Web of Science ®Google Scholar
• Cai Y, Wang J, Zhang L, et al. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer. Med Oncol. 2015;32(1):391.
   PubMed Web of Science ®Google Scholar
• Pizer ES, Wood FD, Heine HS, et al. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 1996;56(6):1189–1193.
   PubMed Web of Science ®Google Scholar
• Pizer ES, Jackisch C, Wood FD, et al. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res. 1996;56(12):2745–2747.
   PubMed Web of Science ®Google Scholar
• Liu ZL, Zhou Y, Luo QF, et al. Inhibition of fatty acid synthase supresses osteosarcoma cell invasion and migration. Indian J Pathol Microbiol. 2012;55(2):163–169.
   PubMed Web of Science ®Google Scholar
• Liu ZL, Wang G, Peng AF, et al. Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis. Oncol Lett. 2012;4(5):878–882.
   PubMed Web of Science ®Google Scholar
• Gelebart P, Zak Z, Anand M, et al. Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma. PLoS One. 2012;7(4):e33738.
   PubMed Web of Science ®Google Scholar
• Bhatt AP, Jacobs SR, Freemerman AJ, et al. Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. Proc Natl Acad Sci U S A. 2012;109(29):11818–11823.
   PubMed Web of Science ®Google Scholar
• Visca P, Sebastiani V, Botti C, et al. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res. 2004;24(6):4169–4173.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Ma J, Chavarro JE, et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010;28(25):3958–3964.
   PubMed Web of Science ®Google Scholar
• Corominas-Faja B, Vellon L, Cuyàs E, et al. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. Histol Histopathol. 2017;32(7):687–698.
   PubMed Web of Science ®Google Scholar
• Silva SD, Cunha IW, Younes RN, et al. ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas. Oral Dis. 2010;16(8):774–780.
   PubMed Web of Science ®Google Scholar
• Hamada S, Horiguchi A, Asano T, et al. Prognostic impact of fatty acid synthase expression in upper urinary tract urothelial carcinoma. Jpn J Clin Oncol. 2014;44(5):486–492.
   PubMed Web of Science ®Google Scholar
• Horiguchi A, Asano T, Asano T, et al. Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J Urol. 2008;180(3):1137–1140.
   PubMed Web of Science ®Google Scholar
• Walter K, Hong S-M, Nyhan S, et al. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2380–2385.
   PubMed Web of Science ®Google Scholar
• Wang Y, Kuhajda FP, Li JN, et al. Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett. 2001;167(1):99–104.
   PubMed Web of Science ®Google Scholar
• Long Q.Q, Yi Y-X, Qiu J, et al. Fatty acid synthase (FASN) levels in serum of colorectal cancer patients: correlation with clinical outcomes. Tumour Biol. 2014;35(4):3855–3859.
   PubMedGoogle Scholar
• Ito T, Sato K, Maekawa H, et al. Elevated levels of serum fatty acid synthase in patients with gastric carcinoma. Oncol Lett. 2014;7(3):616–620.
   PubMed Web of Science ®Google Scholar
• Ishii S, Iizuka K, Miller BC, et al. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci U S A. 2004;101(44):15597–15602.
   PubMed Web of Science ®Google Scholar
• Schcolnik-Cabrera A, Chávez-Blanco A, Domínguez-Gómez G, et al. Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. Am J Cancer Res. 2017;7(5):1107–1135.
   PubMed Web of Science ®Google Scholar
• Ueda, S.M., Yap KL, Davidson B, et al. Expression of fatty acid synthase depends on nac1 and is associated with recurrent ovarian serous carcinomas. J Oncol. 2010;2010:285191.
   PubMedGoogle Scholar
• Gang X, Yang Y, Zhong J, et al. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth. Oncotarget. 2016;7(12):15135–15149.
   PubMedGoogle Scholar
• Santolla MF, Lappano R, De Marco P, et al. G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17beta-estradiol in cancer cells and cancer-associated fibroblasts. J Biol Chem. 2012;287(52):43234–43245.
   PubMed Web of Science ®Google Scholar
• Graner E, Tang D, Rossi S, et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell. 2004;5(3):253–261.
   PubMed Web of Science ®Google Scholar
• Shah US, Dhir R, Gollin SM, et al. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol. 2006;37(4):401–409.
   PubMed Web of Science ®Google Scholar
• Prasad A, Rabionet R, Espinet B, et al. Identification of gene mutations and fusion genes in patients with Sézary Syndrome. J Invest Dermatol. 2016;136(7):1490–1499.
   PubMed Web of Science ®Google Scholar
• Lim B, Kim C, Kim J.H, et al. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. Oncotarget. 2016;7(7):8055–8066.
   PubMedGoogle Scholar
• Benjamin DI, Li DS, Lowe W, et al. Diacylglycerol metabolism and signaling is a driving force underlying FASN inhibitor sensitivity in cancer cells. ACS Chem Biol. 2015;10(7):1616–1623.
   PubMed Web of Science ®Google Scholar
• Angeles TS, Hudkins RL. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors. Expert Opin Drug Discov. 2016;11(12):1187–1199.
   PubMed Web of Science ®Google Scholar
• Nomura S, Horiuchi T, Omura S, et al. The action mechanism of cerulenin. I. Effect of cerulenin on sterol and fatty acid biosynthesis in yeast. J Biochem. 1972;71(5):783–796.
   PubMed Web of Science ®Google Scholar
• Pizer ES, Chrest FJ, DiGiuseppe JA, et al. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res. 1998;58(20):4611–4615.
   PubMed Web of Science ®Google Scholar
• Hogan S, Fleury A, Hadvary P, et al. Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase. Int J Obes. 1987;11 Suppl 3(Suppl 3:):35–42.
   PubMedGoogle Scholar
• Kridel SJ, Axelrod F, Rozenkrantz N, et al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004;64(6):2070–2075.
   PubMed Web of Science ®Google Scholar
• Dean EJF, Patel GS, Brenner MR, et al. H Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640. J Clin Oncol. 2016;34:2512.
   Web of Science ®Google Scholar
• Mencher SK, Wang LG. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol. 2005;5:3.
   PubMedGoogle Scholar
• Pemble CWT, Johnson LC, Kridel SJ, et al. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol. 2007;14(8):704–709.
   PubMed Web of Science ®Google Scholar
• Yang, P.Y., Liu K, Ngai MH, et al. Activity-based proteome profiling of potential cellular targets of Orlistat--an FDA-approved drug with anti-tumor activities. J Am Chem Soc. 2010;132(2):656–666.
   PubMed Web of Science ®Google Scholar
• Wang J, Cui S, Zhang X, et al. High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer. PLoS One. 2013;8(4):e62876.
   PubMed Web of Science ®Google Scholar
• Shirota T, Ojima H, Hiraoka N, et al. Heat shock protein 90 is a potential therapeutic target in cholangiocarcinoma. Mol Cancer Ther. 2015;14(9):1985–1993.
   PubMed Web of Science ®Google Scholar
• Pick E, Kluger Y, Giltnane JM, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 2007;67(7):2932–2937.
   PubMed Web of Science ®Google Scholar
• Jhaveri K, Wang R, Teplinsky E, et al. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Res. 2017;19(1):89.
   PubMedGoogle Scholar
• Cardin DB, Thota R, Goff LW, et al. A phase II study of ganetespib as second-line or third-line therapy for metastatic pancreatic cancer. Am J Clin Oncol. 2017 Mar 15. doi: 10.1097/COC.0000000000000377. [Epub ahead of print]
   Web of Science ®Google Scholar
• Jhaveri K, Chandarlapaty S, Lake D, et al. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer. 2014;14(3):154–160.
   PubMed Web of Science ®Google Scholar
• Jhaveri K, Modi S. Ganetespib: research and clinical development. Onco Targets Ther. 2015;8:1849–1858.
   PubMed Web of Science ®Google Scholar
• Parker AL, Teo WS, McCarroll JA, et al. An emerging role for tubulin isotypes in modulating cancer biology and chemotherapy resistance. Int J Mol Sci. 2017;18(7).
   Web of Science ®Google Scholar
• Cirillo L, Gotta M, Meraldi P. The elephant in the room: the role of microtubules in cancer. Adv Exp Med Biol. 2017;1002:93–124.
   PubMedGoogle Scholar
• Heuer TS, Ventura R, Mordec K, et al. FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and fasn inhibition-mediated effects on oncogenic signaling and gene expression. EBioMedicine. 2017;16:51–62.
   PubMed Web of Science ®Google Scholar
• Moss SE, Morgan RO. The annexins. Genome Biol. 2004;5(4):219.
   PubMed Web of Science ®Google Scholar
• Wang CY, Lin CF. Annexin A2: its molecular regulation and cellular expression in cancer development. Dis Markers. 2014;2014:308976.
   PubMedGoogle Scholar
• Sharma MC, Tuszynski GP, Blackman MR, et al. Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer. Cancer Lett. 2016;373(1):27–35.
   PubMed Web of Science ®Google Scholar
• Colell A, Green DR, Ricci J.E. Novel roles for GAPDH in cell death and carcinogenesis. Cell Death Differ. 2009;16(12):1573–1581.
   PubMed Web of Science ®Google Scholar
• Chambers SK, Kacinski BM, Ivins CM, et al. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res. 1997;3(6):999–1007.
   PubMed Web of Science ®Google Scholar
• Azam S, Jouvet N, Jilani A, et al. Human glyceraldehyde-3-phosphate dehydrogenase plays a direct role in reactivating oxidized forms of the DNA repair enzyme APE1. J Biol Chem. 2008;283(45):30632–30641.
   PubMed Web of Science ®Google Scholar
• Carujo S, Estanyol JM, Ejarque A, et al. Glyceraldehyde 3-phosphate dehydrogenase is a SET-binding protein and regulates cyclin B-cdk1 activity. Oncogene. 2006;25(29):4033–4042.
   PubMed Web of Science ®Google Scholar
• Liu K, Tang Z, Huang A, et al. Glyceraldehyde-3-phosphate dehydrogenase promotes cancer growth and metastasis through upregulation of SNAIL expression. Int J Oncol. 2017;50(1):252–262.
   PubMed Web of Science ®Google Scholar
• Kumagai S, Narasaki R, Hasumi K. Glucose-dependent active ATP depletion by koningic acid kills high-glycolytic cells. Biochem Biophys Res Commun. 2008;365(2):362–368.
   PubMed Web of Science ®Google Scholar
• Wang W, Nag S, Zhang X, et al. Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications. Med Res Rev. 2015;35(2):225–285.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhu X, Zhu J, et al. Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. Oncol Rep. 2007;18(4):943–951.
   PubMed Web of Science ®Google Scholar
• Huang XP, Zhao C-X, Li Q-J, et al. Alteration of RPL14 in squamous cell carcinomas and preneoplastic lesions of the esophagus. Gene. 2006;366(1):161–168.
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee M-Y, Cho KC, et al. Alterations in mRNA expression of ribosomal protein S9 in hydrogen peroxide-treated neurotumor cells and in rat hippocampus after transient ischemia. Neurochem Res. 2003;28(6):925–931.
   PubMed Web of Science ®Google Scholar
• Lindstrom MS, Zhang Y. Ribosomal protein S9 is a novel B23/NPM-binding protein required for normal cell proliferation. J Biol Chem. 2008;283(23):15568–15576.
   PubMed Web of Science ®Google Scholar
• Lindstrom MS, Nister M. Silencing of ribosomal protein S9 elicits a multitude of cellular responses inhibiting the growth of cancer cells subsequent to p53 activation. PLoS One. 2010;5(3):e9578.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cheong D, Chan S, et al. Ribosomal protein L7a gene is up-regulated but not fused to the tyrosine kinase receptor as chimeric trk oncogene in human colorectal carcinoma. Int J Oncol. 2000;16(4):757–762.
   PubMed Web of Science ®Google Scholar
• Ziemiecki A, Müller RG, Fu XC, et al. Oncogenic activation of the human trk proto-oncogene by recombination with the ribosomal large subunit protein L7a. Embo J. 1990;9(1):191–196.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Lin H, Li Z, et al. Modulation of expression of ribosomal protein L7a (rpL7a) by ethanol in human breast cancer cells. Breast Cancer Res Treat. 2001;69(1):29–38.
   PubMed Web of Science ®Google Scholar
• Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol. 1999;39(1):41–46.
   PubMed Web of Science ®Google Scholar
• Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995;35(11):1103–1108.
   PubMed Web of Science ®Google Scholar
• Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag. 2007;3(6):817–821.
   PubMedGoogle Scholar
• Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs. 2006;66(12):1625–1656.
   PubMed Web of Science ®Google Scholar
• Little JL, Wheeler FB, Fels DR, et al. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res. 2007;67(3):1262–1269.
   PubMed Web of Science ®Google Scholar
• Fujiwara J, Sowa Y, Horinaka M, et al. The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells. Int J Oncol. 2012;40(5):1483–1491.
   PubMed Web of Science ®Google Scholar
• Cervantes-Madrid D, Duenas-Gonzalez A. Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids. Oncol Rep. 2015;34(3):1533–1542.
   PubMed Web of Science ®Google Scholar
• Knowles LM, Axelrod F, Browne CD, et al. A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem. 2004;279(29):30540–30545.
   PubMed Web of Science ®Google Scholar
• Knowles LM, Yang C, Osterman A, et al. Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J Biol Chem. 2008;283(46):31378–31384.
   PubMed Web of Science ®Google Scholar
• Zhou W, Han WF, Landree LE, et al. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res. 2007;67(7):2964–2971.
   PubMed Web of Science ®Google Scholar
• Menendez JA, Vellon L, Lupu R. The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. Int J Gynecol Cancer. 2006;16(1):219–221.
   PubMed Web of Science ®Google Scholar
• Huang, H.Q. Tang J, Zhou ST, et al. Orlistat, a novel potent antitumor agent for ovarian cancer: proteomic analysis of ovarian cancer cells treated with Orlistat. Int J Oncol. 2012;41(2):523–532.
   PubMed Web of Science ®Google Scholar
• Yang C.S, Matsuura K, Huang N-J, et al. Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death. Oncogene. 2015;34(25):3264–3272.
   PubMed Web of Science ®Google Scholar
• Chuang H.Y, Chang Y.F, Hwang J.J. Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal. Biomed Pharmacother. 2011;65(4):286–292.
   PubMed Web of Science ®Google Scholar
• Dowling S, Cox J, Cenedella RJ. Inhibition of fatty acid synthase by Orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo. Lipids. 2009;44(6):489–498.
   PubMed Web of Science ®Google Scholar
• Agostini M, Almeida LY, Bastos DC, et al. The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas. Mol Cancer Ther. 2014;13(3):585–595.
   PubMed Web of Science ®Google Scholar
• Xiao X, Liu H, Li X. Orlistat treatment induces apoptosis and arrests cell cycle in HSC-3 oral cancer cells. Microb Pathog. 2017;112:15–19.
   PubMed Web of Science ®Google Scholar
• Mims J, Bansal N, Bharadwaj MS, et al. Energy metabolism in a matched model of radiation resistance for head and neck squamous cell cancer. Radiat Res. 2015;183(3):291–304.
   PubMed Web of Science ®Google Scholar
• Deepa PR, Vandhana S, Jayanthi U, et al. Therapeutic and toxicologic evaluation of anti-lipogenic agents in cancer cells compared with non-neoplastic cells. Basic Clin Pharmacol Toxicol. 2012;110(6):494–503.
   PubMed Web of Science ®Google Scholar
• Vandhana S, Coral K, Jayanthi U, et al. Biochemical changes accompanying apoptotic cell death in retinoblastoma cancer cells treated with lipogenic enzyme inhibitors. Biochim Biophys Acta. 2013;1831(9):1458–1466.
   PubMed Web of Science ®Google Scholar
• Grube S, Dünisch P, Freitag D, et al. Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis. J Neurooncol. 2014;118(2):277–287.
   PubMed Web of Science ®Google Scholar
• Wysham WZ, Roque DR, Han J, et al. Effects of fatty acid synthase inhibition by orlistat on proliferation of endometrial cancer cell lines. Target Oncol. 2016;11(6):763–769.
   PubMed Web of Science ®Google Scholar
• Olsen AM, Eisenberg BL, Kuemmerle NB, et al. Fatty acid synthesis is a therapeutic target in human liposarcoma. Int J Oncol. 2010;36(5):1309–1314.
   PubMed Web of Science ®Google Scholar
• Carvalho MA, Zecchin KG, Seguin F, et al. Fatty acid synthase inhibition with orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer. 2008;123(11):2557–2565.
   PubMed Web of Science ®Google Scholar
• Zecchin KG, Rossato FA, Raposo HF, et al. Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis. Lab Invest. 2011;91(2):232–240.
   PubMed Web of Science ®Google Scholar
• Pallasch CP, Schwamb J, Königs S, et al. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia. 2008;22(3):585–592.
   PubMed Web of Science ®Google Scholar
• Norberg M, Lindhagen E, Kanduri M, et al. Screening for cytotoxic compounds in poor-prognostic chronic lymphocytic leukemia. Anticancer Res. 2012;32(8):3125–3136.
   PubMed Web of Science ®Google Scholar
• Tirado-Vélez JM, Joumady I, Sáez-Benito A, et al. Inhibition of fatty acid metabolism reduces human myeloma cells proliferation. PLoS One. 2012;7(9):e46484.
   PubMed Web of Science ®Google Scholar
• Kant S, Kumar A, Singh SM. Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules. Biochim Biophys Acta. 2012;1820(11):1764–1773.
   PubMed Web of Science ®Google Scholar
• Browne CD, Hindmarsh EJ, Smith JW. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. Faseb J. 2006;20(12):2027–2035.
   PubMed Web of Science ®Google Scholar
• Seguin F, Carvalho MA, Bastos DC, et al. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas. Br J Cancer. 2012;107(6):977–987.
   PubMed Web of Science ®Google Scholar
• Sounni NE, Cimino J, Blacher S, et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab. 2014;20(2):280–294.
   PubMed Web of Science ®Google Scholar
• Paulmurugan R, Bhethanabotla R, Mishra K, et al. Folate receptor-targeted polymeric micellar nanocarriers for delivery of orlistat as a repurposed drug against triple-negative breast cancer. Mol Cancer Ther. 2016;15(2):221–231.
   PubMed Web of Science ®Google Scholar
• Hill TK, Davis AL, Wheeler FB, et al. Development of a self-assembled nanoparticle formulation of orlistat, nano-orl, with increased cytotoxicity against human tumor cell lines. Mol Pharm. 2016;13(3):720–728.
   PubMedGoogle Scholar
• Soucherk, J. J., Davis AL, Hill TK, et al. Combination treatment with orlistat-containing nanoparticles and taxanes is synergistic and enhances microtubule stability in taxane-resistant prostate cancer cells. Mol Cancer Ther. 2017;16(9):1819–1830.
   PubMed Web of Science ®Google Scholar
• Louie SM, Roberts LS, Mulvihill MM, et al. Cancer cells incorporate and remodel exogenous palmitate into structural and oncogenic signaling lipids. Biochim Biophys Acta. 2013 Oct;1831(10):1566–1572.
   PubMed Web of Science ®Google Scholar
• Baumann J, Wong J, Sun Y, et al. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells. BMC Cancer. 2016;16:551.
   PubMed Web of Science ®Google Scholar
• Al-Bahlani S, Al-Lawati H, Al-Adawi M, et al. Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis. Apoptosis. 2017;22(6):865–876.
   PubMed Web of Science ®Google Scholar
• Mahon F.X. Discontinuation of TKI therapy and ‘functional’ cure for CML. Best Pract Res Clin Haematol. 2016;29(3):308–313.
   PubMed Web of Science ®Google Scholar
• Ocana A, Tannock IF. When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst. 2011;103(1):16–20.
   PubMedGoogle Scholar
• Arnedos M, Soria J-C, Andre F, et al. Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community? Cancer Treat Rev. 2014;40(10):1192–1198.
   PubMed Web of Science ®Google Scholar
• Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28(7):1138–1144.
   PubMed Web of Science ®Google Scholar
• Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial Lancet Oncol. 2017;18(10):1307–1316.
   PubMed Web of Science ®Google Scholar
• Liu S, Nikanjam M, Kurzrock R. Dosing de novo combinations of two targeted drugs: towards a customized precision medicine approach to advanced cancers. Oncotarget. 2016;7(10):11310–11320.
   PubMedGoogle Scholar
• Nikanjam M, Liu S, Yang J, et al. Dosing three-drug combinations that include targeted anti- cancer agents: analysis of 37,763 patients. Oncologist. 2017;22(5):576–584.
   PubMed Web of Science ®Google Scholar
• Kato S, Lippman SM, Flaherty KT, et al. The conundrum of genetic “drivers” in benign conditions. J Natl Cancer Inst. 2016;108(8):pii: djw036.
   Google Scholar
• Baker SG. A cancer theory kerfuffle can lead to new lines of research. J Natl Cancer Inst. 2014;107(2):pii: dju405.
   PubMedGoogle Scholar
• Khwairakpam AD, Shyamananda MS, Sailo BL, et al. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment. Curr Drug Targets. 2015;16(2):156–163.
   PubMed Web of Science ®Google Scholar
• Wang C, Rajput S, Watabe K, et al. Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Front Biosci (Schol Ed). 2010;2:515–526.
   PubMedGoogle Scholar